Completed PHASE2 INTERVENTIONAL 1-arm NCT01027208

A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline

A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline And Who Are Taxane Resistant Who Have Completed Study CA163107 And Who Are Benefiting From Continuation On Therapy With Ixabepilone

Sponsor: R-Pharm

Conditions Metastatic Breast Cancer

Interventions Ixabepilone

Updated 7 times since 2017 Last updated: Jan 27, 2017 Started: Dec 31, 2006 Primary completion: Jan 31, 2007 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01027208, this PHASE2 trial focuses on Metastatic Breast Cancer and remains completed. Sponsored by R-Pharm, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

R-Pharm

Data source: R-Pharm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bunkyo-Ku, Japan , Chuo-Ku, Japan , Fukuoka, Japan , Iruma-Gun, Japan , Isehara-Shi, Japan , Kagoshima, Japan , Kashiwa-Shi, Japan , Matabashi-Shi, Japan , Nagoya, Japan , Niigata, Japan and 4 more locations